• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

    3/21/24 4:42:13 PM ET
    $ASLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email
    SC 13G 1 ea0202197-13gintra_aslan.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.      )*

     

    ASLAN Pharmaceuticals Limited

     

    (Name of Issuer)

     

    Ordinary shares, par value $0.01 per share

     

    (Title of Class of Securities)

     

    04522R200**

    (CUSIP Number)

     

    March 12, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐ Rule 13d-1(b)
    b. ☒Rule 13d-1(c)
    c. ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the ordinary shares of the Issuer. CUSIP number 04522R200 has been assigned to the American Depositary Shares of the Issuer, which are quoted on The New York Stock Exchange under the symbol “SOS.” Each such American Depositary Share represents twenty-five (25) ordinary shares of the Issuer.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8

     

     

    CUSIP No. 04522R200

     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization         United States of America
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 25,000,000
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 25,000,000
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 25,000,000 (see Item 4)

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11. Percent of Class Represented by Amount in Row (9) 4.4% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 8

     

     

    CUSIP No. 04522R200

     

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization         United States of America
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 25,000,000
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 25,000,000
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 25,000,000 (see Item 4)

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11. Percent of Class Represented by Amount in Row (9) 4.4% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. 04522R200

     

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization         Delaware
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 25,000,000
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 25,000,000
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person 25,000,000 (see Item 4)

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11. Percent of Class Represented by Amount in Row (9) 4.4% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer

     

    ASLAN Pharmaceuticals Limited (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    3 Temasek Avenue

    Level 18 Centennial Tower

    Singapore 03919021

     

    Item 2.

     

    (a)Name of Person Filing
    (b)Address of Principal Business Office or, if none, Residence
    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Ordinary shares, par value $0.01 per share, of the Issuer (the “Ordinary Shares”). All Ordinary Shares reported herein as being held or beneficially owned by the Reporting Persons are represented by American Depositary Shares of the Issuer (the “ADSs”), which are quoted on The New York Stock Exchange under the symbol “SOS.” Each ADS represents twenty-five (25) Ordinary Shares.

     

    (e)CUSIP Number

     

    There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 04522R200 has been assigned to the ADSs.

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4.Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on March 12, 2024 (the “SPA”) (as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on March 13, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 25,000,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such Ordinary Shares in the aggregate represent beneficial ownership of approximately 5.6% of the Ordinary Shares, based on (1) 420,297,550 Ordinary Shares outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 25,000,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 25,000,000 Ordinary Shares issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (the “Intracoastal Warrant”) because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 50,000,000 Ordinary Shares.

     

    (ii) As of the close of business on March 21, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 25,000,000 Ordinary Shares issuable upon exercise of the Intracoastal Warrant, and all such Ordinary Shares in the aggregate represent beneficial ownership of approximately 4.4% of the Ordinary Shares, based on (1) 420,297,550 Ordinary Shares outstanding prior to the execution of the SPA as reported to the Reporting Persons by the Issuer, plus (2) 125,000,000 Ordinary Shares in the aggregate issued at the closing of the transaction contemplated by the SPA and (3) 25,000,000 Ordinary Shares issuable upon exercise of the Intracoastal Warrant.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 25,000,000.

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of 25,000,000.

     

    Page 6 of 8

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 21, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 8 of 8

     

    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN

    DatePrice TargetRatingAnalyst
    7/9/2021$8.00Buy
    Jefferies
    More analyst ratings

    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

      Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper

      7/17/24 7:25:04 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

      SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff

      7/15/24 7:30:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

      SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C

      6/14/24 4:54:19 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/21/24 4:42:13 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/19/24 4:30:30 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

      SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      2/14/24 4:45:26 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Financials

    Live finance-specific insights

    See more
    • ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

      - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology

      9/27/21 6:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited

      25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      9/6/24 7:41:52 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited

      SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      8/8/24 11:36:38 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ASLAN Pharmaceuticals Limited

      6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)

      7/17/24 7:29:55 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Leadership Updates

    Live Leadership Updates

    See more
    • ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

      New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p

      3/6/24 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

      - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President

      3/15/22 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

      MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

      12/6/21 7:00:00 AM ET
      $ASLN
      $IQV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

      Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      7/9/21 7:45:23 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously

      3/17/21 6:40:11 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care